David R. Berk, MD

Vice President, Clinical Development
Arcutis Biotherapeutics, Inc.

Poster(s):

• (102) Caregiver-reported outcomes from the phase 3 INTEGUMENT-PED trial of children aged 2–5 years with atopic dermatitis and treated with roflumilast cream 0.05%
  Wednesday, October 29, 2025

• (103) Efficacy and safety of roflumilast foam 0.3% in patients with psoriasis of the scalp and body in the phase 3 ARRECTOR trial
  Wednesday, October 29, 2025